LIAISON XL MUREX HCV Ab

FDA Premarket Approval P190011 S002

This medical device record is a pma supplement. A supplement may have changed the device description/function or indication from that approved in the original pma. Be sure to look at the original pma record for more information.

Pre-market Approval Supplement Details

Approval for software version change to the liaison xl analyzer software.

DeviceLIAISON XL MUREX HCV Ab
Generic NameAssay, Enzyme Linked Immunosorbent, Hepatitis C Virus
ApplicantDiaSorin Inc.
Date Received2020-06-18
Decision Date2020-08-06
PMAP190011
SupplementS002
Product CodeMZO 
Advisory CommitteeMicrobiology
Supplement TypeReal-time Process
Supplement ReasonChange Design/components/specifications/material
Expedited ReviewNo
Combination Product No
Applicant Address DiaSorin Inc. 1951 Northwestern Avenue stillwater, MN 55082-0285

Supplemental Filings

Supplement NumberDateSupplement Type
P190011Original Filing
S004 2021-05-27 Real-time Process
S003
S002 2020-06-18 Real-time Process
S001 2020-02-13 Real-time Process

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.